Pacific Biosciences shares rise 1.35% premarket after partnering with EpiCypher for novel insights in chromatin biology.

Pacific Biosciences Of California, Inc. rose 1.35% in premarket trading, with the company announcing a partnership with EpiCypher to deliver novel insights in chromatin biology. The collaboration brings EpiCypher's CUTANA Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, providing researchers with a new way to see chromatin biology at single-molecule resolution. This advanced multi-omic whole genome sequencing (WGS) assay simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules, offering a powerful new approach to understand gene regulation.